Isis Pharmaceuticals to receive $7.5M from Alnylam

Isis Pharmaceuticals (ISIS) announced that it will receive $7.5M from Alnylam Pharmaceuticals (ALNY) from the recently announced alliance between Genzyme, a Sanofi company (SNY), and Alnylam. In addition, Isis has the potential to receive royalties on products and a portion of future milestone payments. This transaction underscores the value of Isis' innovation and the leadership role Isis has played in the field of nucleic acid based therapeutics.

View Comments (1)